Clinical Trial Update: Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating endocrine therapy for HER2-negative, low-risk invasive breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: HER2/Neu Negative, Invasive Breast Carcinoma | Phase 4 | Status: WITHDRAWN